These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26289352)

  • 1. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials.
    Mead G; Hackett ML; Lundström E; Murray V; Hankey GJ; Dennis M
    Trials; 2015 Aug; 16():369. PubMed ID: 26289352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis.
    Graham C; Lewis S; Forbes J; Mead G; Hackett ML; Hankey GJ; Gommans J; Nguyen HT; Lundström E; Isaksson E; Näsman P; Rudberg AS; Dennis M
    Trials; 2017 Dec; 18(1):627. PubMed ID: 29282099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT.
    Dennis M; Forbes J; Graham C; Hackett M; Hankey GJ; House A; Lewis S; Lundström E; Sandercock P; Mead G
    Health Technol Assess; 2020 May; 24(22):1-94. PubMed ID: 32452356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.
    EFFECTS Trial Collaboration
    Lancet Neurol; 2020 Aug; 19(8):661-669. PubMed ID: 32702335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.
    AFFINITY Trial Collaboration
    Lancet Neurol; 2020 Aug; 19(8):651-660. PubMed ID: 32702334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden.
    Lundström E; Isaksson E; Näsman P; Wester P; Mårtensson B; Norrving B; Wallén H; Borg J; Dennis M; Mead G; Hankey GJ; Hackett ML; Sunnerhagen KS;
    Trials; 2020 Feb; 21(1):233. PubMed ID: 32111264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
    FOCUS Trial Collaboration
    Lancet; 2019 Jan; 393(10168):265-274. PubMed ID: 30528472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis.
    Mead GE; Graham C; Billot L; Näsman P; Lundström E; Lewis S; Hankey GJ; Hackett ML; Forbes J; Dennis M;
    Trials; 2020 Nov; 21(1):971. PubMed ID: 33239053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.
    Hankey GJ; Hackett ML; Almeida OP; Flicker L; Mead GE; Dennis MS; Etherton-Beer C; Ford AH; Billot L; Jan S; Lung T; Lundström E; Sunnerhagen KS; Anderson CS; Thang-Nguyen H; Gommans J; Yi Q;
    Stroke; 2021 Aug; 52(8):2502-2509. PubMed ID: 34015940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.
    Lundström E; Isaksson E; Greilert Norin N; Näsman P; Wester P; Mårtensson B; Norrving B; Wallén H; Borg J; Hankey GJ; Hackett ML; Mead GE; Dennis MS; Sunnerhagen KS
    Stroke; 2021 Oct; 52(10):3082-3087. PubMed ID: 34465201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual patient data meta-analysis of the effects of fluoxetine on functional outcomes after acute stroke.
    Mead G; Graham C; Lundström E; Hankey GJ; Hackett ML; Billot L; Näsman P; Forbes J; Dennis M
    Int J Stroke; 2024 Aug; 19(7):798-808. PubMed ID: 38497332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial.
    Bembenek JP; Niewada M; Kłysz B; Mazur A; Kurczych K; Głuszkiewicz M; Członkowska A
    Neurol Neurochir Pol; 2020; 54(6):544-551. PubMed ID: 33373036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT.
    Sprigg N; Flaherty K; Appleton JP; Al-Shahi Salman R; Bereczki D; Beridze M; Ciccone A; Collins R; Dineen RA; Duley L; Egea-Guerrero JJ; England TJ; Karlinski M; Krishnan K; Laska AC; Law ZK; Ovesen C; Ozturk S; Pocock SJ; Roberts I; Robinson TG; Roffe C; Peters N; Scutt P; Thanabalan J; Werring D; Whynes D; Woodhouse L; Bath PM
    Health Technol Assess; 2019 Jul; 23(35):1-48. PubMed ID: 31322116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Marquez-Romero JM; Arauz A; Ruiz-Sandoval JL; Cruz-Estrada Ede L; Huerta-Franco MR; Aguayo-Leytte G; Ruiz-Franco A; Silos H
    Trials; 2013 Mar; 14():77. PubMed ID: 23510124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke.
    Winkel P; Bath PM; Gluud C; Lindschou J; van der Worp HB; Macleod MR; Szabo I; Durand-Zaleski I; Schwab S;
    Trials; 2017 Nov; 18(1):573. PubMed ID: 29187242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised, stepped-wedge cluster trial within the EFFECTS trial.
    Lundström E; Isaksson E; Wester P; Laska AC; Näsman P
    Trials; 2018 Jan; 19(1):14. PubMed ID: 29310679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Very Early Rehabilitation Trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial.
    Langhorne P; Wu O; Rodgers H; Ashburn A; Bernhardt J
    Health Technol Assess; 2017 Sep; 21(54):1-120. PubMed ID: 28967376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury.
    Presneill J; Little L; Nichol A; French C; Cooper DJ; Haddad S; Duranteau J; Huet O; Skrifvars M; Arabi Y; Bellomo R; ;
    Trials; 2014 Dec; 15():501. PubMed ID: 25528574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.